The creation of a bio-artificial liver device could assist liver failure patients awaiting liver transplantation or regeneration by temporarily replacing liver function. The bio- artificial liver device being designed in our laboratory utilises the hepatoblastoma- derived HepG2 cell line. Despite limited liver specific functions whilst in monolayer culture, cell performance can be significantly improved by alginate encapsulation. However, urea cycle activity, which is the mechanism of ammonia detoxification, remains minimal and thus poses a problem in the removal of nitrogenous waste. The aims of this study were to i) investigate the causes for urea cycle dysfunction in the HepG2 and HepG2-C3A cell lines, and ii) investigate the possibiliti...
Background & Aims Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated into...
Tumorigenicity is an associated risk for transplantation of hepatocytes differentiated from human in...
Liver cell therapy and in vitro models require functional human hepatocytes, the sources of which ar...
Bioartificial livers (BALs) have been developed to provide liver support to patients with end-stage ...
Recently, the first clinical trials on Bioartificial Livers (BALs) loaded with a proliferative human...
The transplantation, engraftment, and expansion of primary hepatocytes have the potential to be an e...
Urea cycle (UC) is the main pathway of ammonium removal. A deficiency in any of the five classical e...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
Ornithine transcarbamylase deficiency (OTCD) is a monogenic disease of ammonia metabolism in hepatoc...
Liver disease is a leading cause of mortality in the United States. Tissue engineering and regenerat...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
BACKGROUND: Tumorigenicity is an associated risk for transplantation of hepatocytes differentiated f...
BACKGROUND & AIMS Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated in...
The selection of a cell type for bioartificial liver (BAL) systems for the treatment of patients wit...
Background & Aims Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated into...
Tumorigenicity is an associated risk for transplantation of hepatocytes differentiated from human in...
Liver cell therapy and in vitro models require functional human hepatocytes, the sources of which ar...
Bioartificial livers (BALs) have been developed to provide liver support to patients with end-stage ...
Recently, the first clinical trials on Bioartificial Livers (BALs) loaded with a proliferative human...
The transplantation, engraftment, and expansion of primary hepatocytes have the potential to be an e...
Urea cycle (UC) is the main pathway of ammonium removal. A deficiency in any of the five classical e...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
Ornithine transcarbamylase deficiency (OTCD) is a monogenic disease of ammonia metabolism in hepatoc...
Liver disease is a leading cause of mortality in the United States. Tissue engineering and regenerat...
Urea cycle disorders are incurable enzymopathies that affect nitrogen metabolism and typically lead ...
BACKGROUND: Tumorigenicity is an associated risk for transplantation of hepatocytes differentiated f...
BACKGROUND & AIMS Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated in...
The selection of a cell type for bioartificial liver (BAL) systems for the treatment of patients wit...
Background & Aims Patient-derived human induced pluripotent stem cells (hiPSCs) differentiated into...
Tumorigenicity is an associated risk for transplantation of hepatocytes differentiated from human in...
Liver cell therapy and in vitro models require functional human hepatocytes, the sources of which ar...